As of April 2026, a GLP-1 is prescription-only in the U.S
New users of GLP-1RAs were matched based on age, demographics, comorbidities and medication use by using 1:1 propensity matching with other glucose-lowering drugs
When both conditions occur together, the risk of heart disease, stroke, kidney disorders, and certain cancers increases
In the U.S., prescriptions for these drugs among obese patients jumped from 21,000 in 2019 to 174,000 in 2023
Final Thoughts ZepBound and Wegovy it is not always easy to determine which of those is preferable, although understanding the pros and /or cons of each will help
All GLP-1 drugs work by slowing gastric emptying to some degree, though individual responses vary